


#440 - The Development and Performance of the GeoMx[®] Spatial Proteogenomic Workflow for the Detection of Both RNA and Protein on a Single FFPE Slide




Shilah A. Bonnett, Giang Ong, Alyssa Rosenbloom, Mark Conner, Aric Rininger, Dan Newhouse, Felicia New, Hiromi Sato, Chi Phan, Saskia Ilcisin, John Lyssand, Gary Geiss, and Joseph M. Beechem

Introduction


The GeoMx[®] DSP enables spatially resolved, high-plex digital quantitation of proteins (≥ 147 -plex) and RNA (up to 18,000-plex) from FFPE or FF samples^[1-3]. This technology utilizes unique affinity reagents antibodies for protein or ISH probes for RNA coupled to UV photocleavable oligonucleotide barcodes. Tissue samples are co-incubated with these affinity reagents and fluorescent markers, then subsequently imaged using fluorescence microscopy. Oligonucleotide barcodes are then precisely liberated from any area of interest (AOI) with UV-light, collected and quantified with either an nCounter[®] Platform or Next-Generation Sequencer (NGS). To fully capture the biological processes that control transcription, translation and protein turnover, the individual RNA and protein datasets can be merged for multiomic analysis. However, technical variations stemming from section-to-section variability and precisely matching ROIs across multiple slides, needs to be taken into consideration when analyzing data. To gain deeper insight and control for these variables, multimodal omics has been used as an alternative approach, which pertains to the simultaneous, co-detection of multiple 'omes' in a single sample. Integration of a multimodal omic approach into the GeoMx workflow would enable a deeper characterization of limited and precious biological samples. Furthermore, the simultaneous assessment of RNA and protein from a single AOI would reduce technical variation associated with two separate, single analyte workflows. To expand upon GeoMx DSP capabilities, we have developed a novel co-detection workflow for NGS readout that allows for the profiling of both RNA and protein from the area of interest (AOI) on a FFPE tissue section^[4]. Here we describe the technical development, performance, and application of the Spatial Proteogenomic workflow using high plex GeoMx Human/Mouse Protein Assays and the GeoMx Human/Mouse Whole Transcriptome Atlas (GeoMx Hu/Mm WTA).

GeoMx Spatial Proteogenomics - High-plex Protein and RNA detection on a Single Slide




GeoMx Spatial Proteogenomic Workflow. The assay takes 4 days from slide prep to data analysis and is only compatible with NGS readout. Prior to staining, samples are subjected to a two-step epitope retrieval process involving HIER under basic conditions followed by proteolytic digestion with 0.1 ug/mL ProK.


Detect high plex RNA & Protein with spatial resolution in segmented Colorectal Cancer



Increased T-cell infiltration observed in Frontal Lobe Giant Cell Glioblastoma vs Glioblastoma



GeoMx Spatial Proteogenomics as a one slide high plex multi-analyte solution for mouse



Conclusion

- The GeoMx Spatial Proteogenomic Workflow allows for the co-detection of proteins (≥ 147 -plex) and RNA (up to 18,000-plex) from a single FFPE sample
- Able to resolve distinct tumor or immune targets when the Spatial Proteogenomic Workflow is used in conjunction with the segmentation capabilities of the GeoMx
- The advantages Spatial Proteogenomic Workflow
 - Enables a deeper characterization of limited and precious biological samples
 - Able to profile both analytes from identical cell population
 - Eliminates technical variability associated with section-to-section variation and matching ROIs across multiple slides

References

- C. R. Merritt et al., Multiplex digital spatial profiling of proteins and RNA in fixed tissue. *Nature Biotechnology* 38, 586-599 (2020)
- D. R. Zollinger, S. E. Lingle, K. Sorg, J. M. Beechem, C. R. Merritt, GeoMx[™] RNA Assay: High Multiplex, Digital, Spatial Analysis of RNA in FFPE Tissue. *Methods Mol Biol* 2148, 331-345 (2020)
- S. M. Zimmerman et al., Spatially resolved whole transcriptome profiling in human and mouse tissue using Digital Spatial Profiling. *bioRxiv*, 2021.2009.2029.462442 (2021)
- S.A. Bonnett, G. Ong, et al., The Development and Performance of a GeoMx Based Proteogenomic Workflow for the Detection of Both RNA and Protein on a Single FFPE Slide. https://www.nanostring.com/wp-content/uploads/2022/01/NP_M4240_Spatial-Proteogenomics_3.pdf
- M. Ghandi et al., Next generation characterization of the Cancer Cell Line Encyclopedia. *Nature* 569, 503-508 (2019)
- West L, Cresswell P. Expanding roles for GILT in immunity. *Curr Opin Immunol*. 2013;25:103-8 (<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3342424/>)
- Jiang W, Zheng F, Yao T, Gong F, Zheng W, Yao N. IFI30 as a prognostic biomarker and correlation with immune infiltrates in glioma. *Ann Transl Med*. 2021 Nov;9(21):1686. doi: 10.21037/atm-21-5569. PMID: 34988195; PMCID: PMC8657103.
- Castellanos JR, Purvis U, Labak CM, Guda MR, Tsung AJ, Velupula KK, Asuthkar S. B7-H3 role in the immune landscape of cancer. *Am J Clin Exp Immunol*. 2017 Jun 15;6(4):66-75. PMID: 28695059; PMCID: PMC5498853.
- Zhu, C., Chen, X., Guan, G., Zou, C., Guo, Q., Cheng, P., Cheng, W., & Wu, A. (2020). IFI30 is a Novel Immune-Related Target with Predicting Value of Prognosis and Treatment Response in Glioblastoma. *Oncotargets and therapy*, 13, 1129-1143. <https://doi.org/10.2147/OTT.S237162>
- Hastings KT, Cresswell P. Disulfide reduction in the endocytic pathway: immunological functions of gamma-interferon-inducible lysosomal thiol reductase. *Antioxid Redox Sign*. 2011 Aug 1;15(3):657-68. doi: 10.1089/ars.2010.3684. Epub 2011 Apr 20. PMID: 21506690; PMCID: PMC3125571.

